Treatment delays worsen survival in early-onset colorectal cancer

Clinical takeaway: In patients under 50 with colorectal cancer, consider the interval from diagnosis to therapy as a modifiable risk. A language barrier may flag those patients most susceptible to delays.

More colorectal cancer is turning up in patients well under screening age, where incidence has climbed about 3% per year over the past 15 years. Delays to treatment are known to cost survival in colorectal cancer. What remained unclear is whether the same penalty applies before 50, and which of these patients are most affected by it.

A recent analysis found that starting definitive therapy more than six weeks after tissue diagnosis was independently associated with worse overall survival, holding after adjustment for stage, sex, tumor site, insurance, and neighborhood vulnerability. The six-week mark follows prior work linking waits beyond roughly 40 days to poorer outcomes. The penalty held stage by stage, from localized through metastatic disease.

Otherwise, these patients did well. Survival outpaced older patients, even at more advanced stages at presentation. Fewer comorbidities and more aggressive treatment, including roughly double the rate of chemotherapy, were likely contributors. Younger and older patients were delayed at similar rates.

The data come from the Texas Cancer Registry, covering more than 112,000 patients diagnosed with colorectal cancer from 2004 to 2019, about 11% of them under 50. Mandatory reporting captures nearly all cases.

Of the social factors examined, only a language barrier tracked with longer waits for younger patients. No other component of the vulnerability index, including socioeconomic status and housing, showed an independent link, and the signal held when language was separated from minority status. Unlike most patient-level risk factors, this one is addressable at the clinic level through interpreter access and navigation.

Source: Heslin RT, et al. JAMA Oncol. 2026 Jun 4. Treatment Delays in Early Age–Onset Colorectal Cancer